Glenmark Launches Adapalene Gel USP 0.1% OTC Pump Packs in US
Glenmark Pharmaceuticals Ltd 路 Press Release 路 06 Oct 2026, 2:09 pm
Glenmark Launches Adapalene Gel USP 0.1% OTC Pump Packs in US Glenmark Therapeutics Inc., USA launched Adapalene Gel USP, 0.1% (OTC) in new pump packs, expanding its US dermatology portfolio. The product is comparable to the active ingredient of Differin Gel, 0.1%. According to Nielsen syndicated data for the 52-week period ending 5th Sep'26, the Differin Gel, 0.1% (OTC) market generated annual sales of approximately $45.8 million. The launch provides a convenient dispensing format available in 15 g and 45 g pack sizes across major retail platforms, enhancing Glenmark's OTC presence.
Original exchange filing (PDF)
More announcements from Glenmark Pharmaceuticals Ltd
- Ichnos Glenmark Innovation (IGI) announces IND submission to US FDA for ISB 2301 路 18 Nov 2026
- Glenmark Pharmaceuticals Inc., USA Launches Authorised Generic of INLYTA (axitinib) Tablets, 1 mg and 5mg 路 16 Nov 2026
- Schedule of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Initmation of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Intimation of Schedule of Analyst / Institutional Investor Meetings 路 10 Nov 2026
- Transcript of the Earnings Call 路 09 Nov 2026
- Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 路 06 Nov 2026
